{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:05:11Z","timestamp":1789707911199,"version":"4.0.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PARP inhibitor-based maintenance has become central to first-line treatment of newly diagnosed advanced ovarian cancer. With expanding therapeutic options, treatment selection increasingly relies on BRCA mutation and homologous recombination deficiency (HRD) status. The 2026 NCCN Guidelines emphasize biomarker-directed maintenance; however, comparative evidence across molecular subgroups remains limited. We conducted an updated network meta-analysis to compare efficacy and safety of PARP inhibitor-based first-line maintenance strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched major databases and conference proceedings to 1 April 2026 for randomized controlled trials evaluating first-line maintenance in newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Eligible interventions included PARP inhibitor monotherapy, PARP inhibitor plus antiangiogenic therapy, antiangiogenic monotherapy, and placebo. Primary analyses focused on progression-free survival (PFS) in BRCA-mutated and HRD-positive populations; secondary and exploratory analyses covered intention-to-treat, HRD-positive non-BRCA-mutated, and homologous recombination proficient populations. Safety outcomes included grade \u22653 adverse events and treatment discontinuation. A frequentist random-effects model was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven trials involving 3,930 patients were included. PARP inhibitor-based maintenance significantly improved PFS versus placebo, with the strongest benefit in BRCA-mutated and HRD-positive populations. PARP inhibitor monotherapy also significantly improved PFS in the HRD-positive non-BRCA-mutated population, supporting clinical relevance of HRD status beyond BRCA mutation alone. Benefit in the intention-to-treat population was smaller than in biomarker-selected populations. Evidence of benefit in the homologous recombination proficient population was inconsistent. Indirect comparisons showed no statistically significant superiority of one active regimen over another. Within the connected network, no statistically significant incremental PFS benefit was established for adding antiangiogenic therapy to PARP inhibition; this comparison was limited by the restricted evidence base for combination therapy and the inability to incorporate PAOLA-1 into the primary network because of network disconnection. No statistically significant evidence indicated that frontline bevacizumab exposure modified the relative PFS benefit. Sensitivity analyses yielded results consistent with the primary analysis. PARP inhibitor monotherapy increased grade \u22653 adverse events versus placebo; comparative safety of combinations remained limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This network meta-analysis supports biomarker-directed PARP inhibitor-based first-line maintenance in advanced ovarian cancer, with the greatest PFS benefit in BRCA-mutated and HRD-positive populations. No active regimen demonstrated statistically significant superiority within the connected network. The incremental benefit of adding antiangiogenic therapy to PARP inhibition remains uncertain because connected-network evidence for combination strategies was limited and PAOLA-1 could not be incorporated into the primary network. These findings should not be interpreted as evidence against the clinical value of olaparib plus bevacizumab or combination maintenance strategies in general. Treatment selection should integrate molecular status, prior bevacizumab exposure, safety, treatment availability, and patient preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261382266.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1884407","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:14Z","timestamp":1789705874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Juntao","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1335196","article-title":"How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature","volume":"14","author":"Arcieri","year":"2024","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature05789","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.6051","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0059","article-title":"Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer","volume":"17","author":"Le Saux","year":"2021","journal-title":"Future Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"B14","unstructured":"Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer (Version 1.2026)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.41648","article-title":"PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: A systematic review and meta-analysis","volume":"8","author":"Petousis","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.37766\/inplasy2025.3.0096","article-title":"Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy","volume":"26","author":"Zhang","year":"2026","journal-title":"Expert Rev Anticancer Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70042","article-title":"Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"76","author":"Wu","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial","volume":"30","author":"Wu","year":"2024","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/ogx.0000000000001120","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1884407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:25Z","timestamp":1789705885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1884407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1884407"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1884407","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1884407"}}